TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market
Holding TCRX?
Track your performance easily

TScan Therapeutics (TCRX) Income Statement

175 Followers

TScan Therapeutics Income Statement

Last quarter (Q2 2024), TScan Therapeutics's total revenue was $536.00K, a decrease of -82.97% from the same quarter last year. In Q2, TScan Therapeutics's net income was $-31.66M. See TScan Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 12.20M$ 21.05M$ 13.54M$ 10.14M$ 1.08M$ 0.00
Cost of Revenue
------
Gross Profit
$ 12.20M$ 21.05M$ 13.54M$ 10.14M--
Operating Expense
$ 123.79M$ 114.51M$ 80.17M$ -58.78M$ 27.32M$ 14.21M
Operating Income
$ -111.59M$ -93.46M$ -66.64M$ -48.64M$ -26.23M$ -14.21M
Net Non Operating Interest Income Expense
$ 7.18M$ 4.24M$ 415.00K$ 16.00K$ 106.00K$ 552.00K
Other Income Expense
------
Pretax Income
$ -104.41M$ -89.22M$ -66.22M$ -48.63M$ -26.13M$ -13.66M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -104.41M$ -89.22M$ -66.22M$ -48.63M$ -26.13M$ -13.66M
Basic EPS
$ -1.04$ -1.36$ -2.75$ -4.17$ -1.11$ -0.57
Diluted EPS
$ -1.04$ -1.36$ -2.75$ -4.17$ -1.11$ -0.57
Basic Average Shares
$ 399.27M$ 65.60M$ 24.05M$ 11.66M$ 23.94M$ 23.94M
Diluted Average Shares
$ 399.27M$ 65.60M$ 24.05M$ 11.66M$ 23.94M$ 23.94M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 123.79M$ 114.51M$ 80.17M$ -58.78M$ 27.32M$ 14.21M
Net Income From Continuing And Discontinued Operation
$ -104.41M$ -89.22M$ -66.22M$ -48.63M$ -26.13M$ -13.66M
Normalized Income
$ -94.85M---$ -26.13M$ -13.66M
Interest Expense
------
EBIT
$ -100.67M$ -85.46M$ -65.05M$ -48.64M$ -26.23M$ -14.21M
EBITDA
$ -75.00M$ -80.10M$ -59.91M$ -51.94M$ -25.00M$ -13.69M
Currency in USD

TScan Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis